Objective: Muscle-specific receptor tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) accounts for 5%-15% of autoimmune MG. MuSK mediates the agrin-signaling pathway and also anchors the collagenic tail subunit (ColQ) of acetylcholinesterase (AChE). The exact molecular target of MuSK-immunoglobulin G (IgG), however, remains elusive. As acetylcholine receptor (AChR) deficiency is typically mild and as cholinesterase inhibitors are generally ineffective, we asked if MuSK-IgG interferes with binding of ColQ to MuSK.
domain of ColQ 7 bind to heparin sulfate proteoglycans, such as perlecan 8 ; and the C-terminal domain of ColQ binds to MuSK. 9 Five percent to 15% of patients with myasthenia gravis (MG) carry antibodies against MuSK (MuSK-immunoglobulin G [IgG]). 10, 11 MuSK-MG patients respond favorably to immunotherapy, but usually do not respond to, or are even worsened by, cholinesterase inhibitors. [12] [13] [14] [15] Anti-AChR antibodies comprise IgG1 and IgG3 moieties that bind complement whereas anti-MuSK antibodies are largely IgG4 that do not activate complement, and complement deposits at the NMJ are sparse. 16 -18 However, the exact target of MuSK-IgG remains elusive. We therefore examined an effect of MuSK-IgG on an interaction between ColQ and MuSK by in vitro and in vivo assays, and found that MuSK-IgG blocks this interaction.
METHODS Patients. We obtained serum from 4
MuSK-MG patients (patients 1-4) and a patient with limbgirdle muscular dystrophy as a control (control 1). We obtained 10 mL peripheral blood from patients 1, 3, 4, and control and residual plasmapheresis fluid from patient 2. We also obtained expired fresh-frozen plasma (control 2) from Dr. Isao Takahashi at the Aichi Red Cross Blood Center with institutional approval. We used sera of patient 2 and control 2 for all the experiments, and sera of patients 1, 3, 4, and control 1 only for the in vitro overlay and in vitro plate binding assays because only small amounts of sera were available from these patients.
Ages and genders of patients 1-4 were a 48-year-old woman, a 30-year-old woman, a 59-year-old man, and a 45-year-old woman, respectively. The titers of anti-MuSK antibodies of patients 1-3 were 22.0 nM, 11.2 nM, and 0.12 nM, respectively (normal Ͻ0.01 nM). Patient 4 was positive for anti-MuSK antibody, but the titer was not determined.
Standard protocol approvals, registrations, and patient consents. We performed all human studies under the institutional review board approvals of the Nagoya University Graduate School of Medicine and the Mayo Clinic, and obtained written informed consents from each patient and a control. We also obtained approvals of the ColqϪ/Ϫ mice studies and the passive IgG transfer studies by the Animal Care and Use Committee of the Nagoya University.
Plasmids. We previously made CMV-based mammalian expression vectors, pTargeT-COLQ and pTargeT-ACHE. 19 To generate hMuSKect-myc, we cloned the extracellular domain (aa 1-393) of human MUSK cDNA (Open Biosystems) into a mammalian expression vector pAPtag-5 (GenHunter) at the NheI and XhoI sites upstream of a myc epitope. For hLRP4N-FLAG, we cloned the extracellular domain (aa 1-1722) of human LRP4 cDNA (Open Biosystems) into the HindIII and XbaI sites upstream of a 3xFLAG epitope of a mammalian expression vector p3XFLAG-CMV-14 (Sigma Aldrich).
Preparation of recombinant human ColQ-tailed AChE. We prepared human ColQ-tailed AChE for in vitro overlay assay and for in vitro plate-binding assay. Both pTargeT-COLQ and pTargeT-ACHE were transfected into HEK293 cells in a 10-cm dish using the calcium phosphate method as described elsewhere. 20 We extracted proteins from the cells in TrisHCl buffer (50 mM Tris-HCl [pH 7.0], 0.5% Triton X-100, 0.2 mM EDTA, leupeptin [2 g/mL], and pepstatin [1 g/mL]) containing 1 M NaCl, and diluted the extracts containing ColQtailed AChE in Tris-HCl buffer containing 0.2 M NaCl and loaded onto the HiTrap Heparin HP columns (GE Healthcare). We washed the columns with 5 volumes of Tris-HCl buffer containing 0.2 M NaCl, and eluted ColQ-tailed AChE with TrisHCl buffer containing 1 M NaCl. We concentrated the eluate with an Amicon Ultra-4 Centrifugal Filter (50K) (Millipore) to 12-Ellman units per mL. The units were normalized with the Torpedo-derived AChE (C2888, Sigma-Aldrich).
Preparation of hMuSKect-myc and hLRP4N-FLAG proteins. We prepared hMuSKect-myc and hLRP4N-FLAG for in vitro plate-binding assays. We introduced a construct carrying either hMuSKect-myc or hLRP4N-FLAG into HEK293 cells in a 10-cm dish using the calcium phosphate method as above. We purified the hMuSKect-myc with the c-myc-Tagged Protein Mild Purification Kit version 2 (MBL), and purified the hLRP4N-FLAG with the Anti-DYKDDDDK-tag Antibody Beads (Wako). We detected purified hMuSKect-myc and hLRP4N-FLAG by anti-myc antibody (9E10, Abcam) and anti-FLAG antibody (M2, SigmaAldrich), respectively (data not shown), and also detected hMuSKect-myc by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by protein staining with the Oriole Fluorescent Gel Stain (Bio-Rad).
Purification of plasma IgG. We purified IgG as described elsewhere 21 with minor modifications. We adjusted plasma to pH 8.0 with 1 M NaOH. While stirring 1 volume of plasma, we slowly added 3.5 volumes of 0.4% rivanol (Tokyo Chemical Industries) in water for 30 minutes. We left the solution overnight at RT, and removed a tenacious yellow precipitate. After filtering the supernatant through Whatman no. 1 paper to remove residual precipitates, we added 8 g of activated charcoal (Wako Chemicals) for 100 mL of the IgG solution and incubated overnight at 4°C to remove rivanol. We then slowly added an equal amount of saturated ammonium sulfate, and again incubated overnight at RT to precipitate crude IgG. We centrifuged the solution at 3,000 ϫ g for 30 minutes, and added saline to the precipitate to form a slurry, which was then transferred to a dialysis tube (Spectra/Por MWCO 50,000, Spectrum Laboratories). We dialyzed the solution in saline at 4°C for 3 hours, followed by dialysis in PBS at 4°C for 2 hours and then overnight. We removed residual charcoals by filtering through a 0.22-m Millex-GP filter (Millipore), and concentrated IgG using Amicon Ultra 50K (Millipore). We confirmed purity of isolated IgG by 6% SDS-PAGE under a nonreducing condition. We also reduced IgG in 4% 2-mercaptoethanol and fractionated the heavy and light chains by 10% SDS-PAGE.
Incubation of purified IgG to a muscle section of
Colq؊/؊ mice. We prepared 10-m-thick sections of quadriceps muscles of ColqϪ/Ϫ mice 22 with a Leica CW3050 -4 cryostat at Ϫ20°C. We blocked nonspecific binding of a muscle section with the blocking buffer that contained 5% sheep serum in PBS at RT for 2 hours. We suspended the purified IgG in the blocking buffer at 50 g/mL, and overlaid it on a muscle section at 4°C overnight. We detected human IgG by FITC-labeled anti-human IgG antibody (02-10-06, KPL), and AChR by Alexa594-labeled ␣-bungarotoxin (Molecular Probes).
In vitro overlay assay. The overlay binding method was essentially as previously described. 23 We overlaid 600 g IgG of patients at 4°C overnight before adding 120-milli-Ellman units of ColQ-tailed AChE.
In vitro plate-binding assay for quantifying ColQMuSK interaction. We coated the Maxi-Sorp Immuno Plate (Nunc) with 0.15 g of purified hMuSKect-myc at 4°C overnight and then incubated it with a blocking buffer that contained 50 mM Tris-HCl (pH 7.4), 0.5% BSA, 0.5% ovalbumin, and 0.5 M NaCl at RT for 1 hour. We incubated the wells with 1 pg to 100 g of IgG of controls 1 and 2 and patients 1-4 at 4°C for 6 hours. We added 0.12-Ellman units of ColQ-tailed AChE as described above. We then quantified the bound ColQtailed AChE by the Ellman method in the presence of 5 ϫ 10 -5 M ethopropazine. 19 Each time before we moved to the next step, we washed the plate 3 times with PBS.
In vitro plate-binding assay for quantifying LRP4-MuSK interaction. We coated the Maxi-Sorp Immuno Plate with 0.15 g of purified hMuSKect-myc as described above, and then blocked with 1% BSA in PBS at RT for 1 hour. We incubated the wells with 1 pg to 100 g of IgG of control 2 and patient 2 at 4°C for 6 hours. We added 0.12 g of purified hLRP4N-FLAG on each well at RT for 2 hours. We then quantified the bound hLRP4N-FALG by anti-FLAG-HRP using the TMB substrate kit (Pierce). Again, between each step, we washed the plates 3 times with PBS.
Passive transfer of human IgG to mice. We made passive transfer model mice as described elsewhere. 24 We intraperitoneally injected 40 mg IgG of control 2 and patient 2 into 6-weekold female C57BL/6J mice every day for 15 days. We sterilized IgG with a 0.22-m filter (Millipore) and dissolved it in 400 L PBS. The mice were killed on day 16 under deep anesthesia. To suppress any active immune response to the human protein, 25 we injected 300 mg/kg of cyclophosphamide monohydrate (10 mg/mL in 0.9% NaCl) intraperitoneally 24 hours after the first IgG injection. We also injected IgG of patient 2 into 2 additional mice to confirm consistency, and analyzed a representative mouse in detail. We detected AChR by Alexa594- 
RESULTS

MuSK-IgG recognizes NMJ of a muscle
section of Colq؊/؊ mouse. We first confirmed that human MuSK-IgG recognizes the mouse NMJ. We isolated IgG from serum of MuSK-MG patients and confirmed the purity of IgG by Coomassie staining of nonreducing ( figure 1A ) and reducing (figure 1B) SDS-PAGEs. We then overlaid MuSK-IgG on quadriceps muscle sections of ColqϪ/Ϫ mice. 22 IgG of control 1 was not bound to the NMJ, whereas IgGs of patients 1 and 2 colocalized to the NMJs ( figure  1C ). Human MuSK-IgG thus has the potential to bind to the mouse NMJ.
In vitro overlay assay discloses that MuSK-IgG blocks binding of ColQ-tailed AChE to the NMJ of a muscle section of Colq؊/؊ mouse. We previously demonstrated that the purified recombinant human ColQtailed AChE protein complex could bind to sections of the frog NMJs 23 and the mouse NMJs (in preparation) in vitro. Using the in vitro overlay assay, we next examined whether MuSK-IgG blocks anchoring of ColQ-tailed AChE to the mouse NMJs. We incubated a muscle section of ColqϪ/Ϫ mice with MuSK-IgG overnight at 4°C and overlaid human ColQ-tailed AChE followed by histologic visualization of ColQ and AChR (figure 2). In the presence of IgG of control 1, ColQ was colocalized with AChRs, whereas, in the presence of 4 MuSK-IgGs, no ColQ signal was observed at the NMJs.
In vitro plate-binding assay shows that MuSK-IgG blocks binding of ColQ-tailed AChE but not of LRP4
to MuSK. We next quantified an effect of MuSK-IgG on an interaction of human ColQ and human MuSK by an in vitro plate-binding assay. We synthesized and purified the myc-tagged extracellular domain of human MuSK (hMuSKect-myc). We then incubated an hMuSKect-coated plate with variable concentrations of control IgG or MuSK-IgG, and added a fixed amount of the purified recombinant human ColQ-tailed AChE. In 2 controls, AChE remained bound even in the presence of 100 g of IgG, whereas in 4 MuSK-MG patients the numbers of bound AChE were proportionally decreased with increasing amounts of the patient's IgG ( figure 3A) . We also examined the effect of MuSK-IgG on the interaction between the extracellular domain of MuSK and LRP4. We found that even at 100 g IgG of control 2 or patient 2 did not block binding of LRP4 to MuSK ( figure 3B ). DISCUSSION Molecular basis of MuSK-MG has been examined in cultured cells 30, 31 as well as in active 28, 29 and passive 24, 26, 27 immunization models. Application of MuSK-MG antibodies to TE671 muscle cells induces inhibition of cell proliferation and secondarily leads to downregulation of AChR and rapsyn. 30 Similarly, MuSK-MG antibodies have no or minimal effect on the cell surface expression of AChR in TE671 and C2C12 muscle cells. 31 Conversely, mice 29 and rabbits 28 immunized with recombinant MuSK develop myasthenic symptoms and NMJ AChR deficiency. Similarly, injection of MuSK-IgG into mice reduces the number of AChRs at the NMJ to 22% of controls, compromises the apposition of the presynaptic and postsynaptic components of the NMJ, 24 and reduces muscle contractility. 27 A recent report demonstrates that MuSK-IgG enhances internalization of MuSK from plasma membrane, which leads to progressive dispersal of postsynaptic AChRs by disruption of the MuSK scaffold and not by disruption of the agrin/LRP4/MuSK signaling pathway. 26 To summarize, MuSK-IgG does not reduce AChR expression in cultured cells, but active and passive immunization of model animals results in AChR deficiency, which is not likely due to blocking of the agrin/LRP4/MuSK pathway. Our findings that MuSK-IgG blocks binding of ColQ but not of LRP4 to MuSK are consistent with these findings. In myotubes of ColqϪ/Ϫ mice, the number of membrane-bound MuSK is prominently reduced, and agrin-mediated phosphorylation of the AChR ␤ subunit and the subsequent clustering of AChR are reduced to 30%-50% of the wild type. 32 Thus, compromised clustering of AChRs at the NMJs in some MuSK-MG patients could result from blocking of ColQ binding to MuSK but not from blocking of LRP4 binding to MuSK.
Although our results predict endplate AChE deficiency in MuSK-MG patients, we found no AChE deficiency in intercostal muscles of one reported 33 and two unreported cases of MuSK-MG. In vitro microelectrode studies showed a normal EPP decay time constant. 34 In the 3 MuSK-MG patients observed by us, the MEPC decay times were shorter than normal, normal, and 2-fold prolonged 33 compared to controls. Thus, our biopsy findings do not indicate that MuSK-MG patients have endplate AChE deficiency. There are 2 plausible explanations for the apparently contradicting observation on the human biopsies and the in vitro and in vivo studies. First, MuSK-IgG does not block binding of ColQtailed AChE to the NMJ to a detectable extent in the patients. ColQ is localized to the synaptic basal lamina via 2 mechanisms: one is by binding to heparin sulfate proteoglycans including perlecan, 7, 8 and the other is by binding to MuSK. 9 We previously reported that both mechanisms are required for in vitro anchoring of human ColQ to the frog NMJ. 23 Reduced clustering of ColQ in our passive transfer model suggests that ColQ needs to bind to at least MuSK in mice. However, binding of ColQ to MuSK is dispensable for clustering ColQ in humans, but is required for facilitating AChR clustering. 32 Second, AChE could be deficient in severely affected muscles but not in the biopsied intercostal muscles. However, the respiratory functions of the patients who had intercostal muscle biopsies were severely compromised. Expression levels of MuSK 35 and ColQ 36 were reported to be different between slow-and fast-twitch muscles in model animals. In active 37 and passive 26 immunization models, slow-twitch diaphragm was more severely affected than fast-twitch tibialis anterior and intercostal muscles. Similar uneven distributions of affected muscles are reported in MuSK-MG patients. 12 Further studies will be required to elucidate the basis of the discrepant observations between mice and humans. 
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